Real time Form 13D and 13G transaction reports:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Due to inconsistent filing format, it is highly recommended that you read the orignal filing form.
- Shares have beem adjusted for stock split.
"Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise"
- Peter Lynch
What is insider trading>>
- Peter Lynch
What is insider trading>>
| Reported DateTime | Transaction Date | Type | Company Symbol | Filed By Symbol | Shares Owned % Owned | Shares Vs. Prev Report | View |
| 2025-06-18 11:08 am Sale | 2025-06-17 | 13D | AN2 Therapeutics, Inc. ANTX | BML Investment Partners, L.P. | 427,432 1.400% | -2,789,991 (-86.72%) | Filing History |
| 2025-06-04 5:44 pm Purchase | 2025-05-28 | 13G | AN2 Therapeutics, Inc. ANTX | Coastlands Capital LP | 2,815,900 9.300% | 2,815,900 (New Position) | Filing History |
| 2025-05-30 5:46 pm Sale | 2025-05-28 | 13D | AN2 Therapeutics, Inc. ANTX | BML Investment Partners, L.P. | 3,217,423 10.700% | -2,532,009 (-44.04%) | Filing History |
| 2025-05-07 10:27 am Unchanged | 2025-05-07 | 13D | AN2 Therapeutics, Inc. ANTX | BML Investment Partners, L.P. | 5,749,432 19.100% | 0 (Unchanged) | Filing History |
| 2025-02-28 7:57 pm Sale | 2024-12-31 | 13G | AN2 Therapeutics, Inc. ANTX | Adjuvant Global Health Technology Fund, L.P. | 2,373,500 7.900% | -100,000 (-4.04%) | Filing History |
| 2025-02-14 6:27 pm Sale | 2024-12-31 | 13G | AN2 Therapeutics, Inc. ANTX | RA CAPITAL MANAGEMENT L.P. | 0 0.000% | -1,999,997 (Position Closed) | Filing History |
| 2025-02-14 4:44 pm Sale | 2024-12-31 | 13G | AN2 Therapeutics, Inc. ANTX | TCG Crossover GP I, LLC | 0 0.000% | -1,555,118 (Position Closed) | Filing History |
| 2025-02-14 4:30 pm Sale | 2024-12-31 | 13G | AN2 Therapeutics, Inc. ANTX | Brii Biosciences Limited | 927,201 3.100% | -121,278 (-11.57%) | Filing History |
| 2025-02-14 11:07 am Unchanged | 2024-12-31 | 13G | AN2 Therapeutics, Inc. ANTX | Frazier Life Sciences Public Fund, L.P. | 0 0.000% | 0 (Unchanged) | Filing History |
| 2025-02-13 4:30 pm Purchase | 2024-12-31 | 13G | AN2 Therapeutics, Inc. ANTX | Easom Eric | 1,893,132 6.200% | 320,962 (+20.42%) | Filing History |
| 2025-02-13 4:28 pm Unchanged | 2024-12-31 | 13G | AN2 Therapeutics, Inc. ANTX | BML Investment Partners, L.P. | 5,749,432 19.200% | 0 (Unchanged) | Filing History |
| 2024-11-14 4:29 pm Sale | 2024-09-30 | 13G | AN2 Therapeutics, Inc. ANTX | BIOTECHNOLOGY VALUE FUND L P | 0 0.000% | -1,563,963 (Position Closed) | Filing History |
| 2024-11-14 4:16 pm Sale | 2024-09-30 | 13G | AN2 Therapeutics, Inc. ANTX | Citadel Advisors LLC | 22 0.000% | -1,556,820 (-100.00%) | Filing History |
| 2024-11-13 4:25 pm Sale | 2024-09-30 | 13G | AN2 Therapeutics, Inc. ANTX | TCG Crossover GP I, LLC | 1,555,118 5.200% | -1,123,091 (-41.93%) | Filing History |
| 2024-08-28 4:02 pm Sale | 2024-08-26 | 13G | AN2 Therapeutics, Inc. ANTX | Octagon Capital Advisors LP | 0 0.000% | -3,009,927 (Position Closed) | Filing History |
| 2024-08-14 9:00 pm Purchase | 2024-08-14 | 13G | AN2 Therapeutics, Inc. ANTX | BML Investment Partners, L.P. | 5,749,432 19.300% | 1,500,000 (+35.30%) | Filing History |
| 2024-08-13 5:40 pm Sale | 2024-08-09 | 13G | AN2 Therapeutics, Inc. ANTX | RA CAPITAL MANAGEMENT L.P. | 1,999,997 6.700% | -3,551,298 (-63.97%) | Filing History |
| 2024-08-12 4:48 pm Purchase | 2024-08-09 | 13G | AN2 Therapeutics, Inc. ANTX | BML Investment Partners, L.P. | 4,249,432 14.200% | 4,249,432 (New Position) | Filing History |
| 2024-07-03 08:02 am Purchase | 2024-06-13 | 13G | AN2 Therapeutics, Inc. ANTX | Octagon Capital Advisors LP | 3,009,927 10.100% | 3,009,927 (New Position) | Filing History |
| 2024-04-10 4:44 pm Purchase | 2024-04-03 | 13G | AN2 Therapeutics, Inc. ANTX | Frazier Life Sciences Public Fund, L.P. | 1,488,889 5.000% | 1,488,889 (New Position) | Filing |